Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00833625 · ClinicalTrials.gov registry record · NA

FDG-PET-CT and Biomarkers in Esophageal Cancer

A NA study of Esophageal Cancer and Gastrointestinal Disease, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT00833625 is a NA study of Esophageal Cancer and Gastrointestinal Disease that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00833625, a NA study of Esophageal Cancer and Gastrointestinal Disease, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn if the results of a positron emission tomography/computed tomography (PET/CT) scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation) can predict how a patient with cancer of the esophagus will respond to chemoradiation. Researchers also want to learn if biomarkers (substances in the body associated with cancer) found in tumor tissue can predict response to chemoradiation.

Interventions

  • PROCEDURE PET/CT (FDG PET/CT)
  • OTHER Biomarker Testings

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2009-02
Est. Completion 2015-12
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00833625

The ClinicalTrials.gov registry entry for NCT00833625 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (94% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which PET/CT (FDG PET/CT) is the first listed.

NCT00833625 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00833625 about?

NCT00833625 is a clinical study titled "FDG-PET-CT and Biomarkers in Esophageal Cancer". The goal of this clinical research study is to learn if the results of a positron emission tomography/computed tomography (PET/CT) scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation) can predict how a patient with cancer of the esophagus will respond to chemoradiation. R...

What is the current status of trial NCT00833625?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2009-02. Estimated completion is 2015-12.

What conditions does trial NCT00833625 study?

This clinical trial studies the following conditions: Esophageal Cancer, Gastrointestinal Disease.

What interventions are being tested in trial NCT00833625?

The interventions under investigation include: PET/CT (FDG PET/CT) (PROCEDURE), Biomarker Testings (OTHER).

Who is sponsoring clinical trial NCT00833625?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00833625 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Esophageal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.